title: Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
abstract: Observational and epidemiological studies suggest that menopausal hormone therapy (MHT) reduces cardiovascular disease (CVD) risk. However, results from prospective trials showed neutral or adverse effects most likely due to differences in participant demographics, such as age, timing of initiation of treatment, and preexisting cardiovascular disease, which reflected in part the lack of basic science information on mechanisms of action of hormones on the vasculature at the time clinical trials were designed. The Kronos Early Estrogen Replacement Study (KEEPS) is a prospective, randomized, controlled trial designed, using findings from basic science studies, to test the hypothesis that MHT when initiated early in menopause reduces progression of atherosclerosis. KEEPS participants are younger, healthier, and within 3 years of menopause thus matching more closely demographics of women in prior observational and epidemiological studies than women in the Women's Health Initiative hormone trials. KEEPS will provide information relevant to the critical timing hypothesis for MHT use in reducing risk for CVD.
authors: Medical Science 4-62, College of Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. miller.virginia@mayo.edu
authors: V M
authors: VM
authors: Miller
authors: D M
authors: DM
authors: Black
authors: E A
authors: EA
authors: Brinton
authors: M J
authors: MJ
authors: Budoff
authors: M I
authors: MI
authors: Cedars
authors: H N
authors: HN
authors: Hodis
authors: R A
authors: RA
authors: Lobo
authors: J E
authors: JE
authors: Manson
authors: G R
authors: GR
authors: Merriam
authors: F
authors: F
authors: Naftolin
authors: N
authors: N
authors: Santoro
authors: H S
authors: HS
authors: Taylor
authors: S M
authors: SM
authors: Harman
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D004311:Double-Blind Method; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011374:Progesterone / Q000008:administration & dosage*; D011446:Prospective Studies; D020551:Pulse Therapy, Drug; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D013997:Time Factors; D057170:Translational Research, Biomedical; D016896:Treatment Outcome; D014481:United States; D016387:Women's Health
chemical_list: D004966:Estrogens, Conjugated (USP); D011374:Progesterone; D004958:Estradiol